We Don’t Kick Diabetics Out for Eating Ice Cream: Issues With Efficacy in Addiction Therapy
This article was originally published in RPM Report
Executive Summary
An Advisory Committee review of Titan’s Probuphine highlights the difficulties of measuring addiction treatment products: how to quantify success when even opioid-positive urine samples can be a good sign.
You may also be interested in...
FDA Plants OB-GYNs on Implant Addiction Therapy Committee; Titan Harvests Yes Vote
An advisory committee reviewing Titan’s Probuphine for abuse dependence leaned heavily on reassuring safety perspectives of two guest members invited for their particular expertise. No, they weren’t addiction experts. They were gynecologists.
A Final Push For US Hepatitis C Eradication Plan In 2024
The Biden Administration is hoping that it can attach funding for a national hepatitis C ‘subscription’ program into the delayed fiscal 2024 appropriations bills.
Menopausal Status Is Another Focus For US FDA Trial Inclusion Efforts
US FDA is emphasizing the need to assess the effects of menopause on drug safety and efficacy as a continuation of the agency’s efforts to encourage clinical trial sponsors to look more systematically for differences in clinical trial subpopulations.